^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD19/CD22 CAR T-cells

    i
    Other names: CD19/CD22 CAR T-cells, CD19/CD22 bicistronic chimeric antigen receptor (CAR) T cells
    Associations

    News

    Trials
    Company:
    National Cancer Institute
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, M.D. Anderson Cancer Center | N=30 --> 0 | Trial completion date: Aug 2023 --> Nov 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2023 --> Nov 2022
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • CAR T-Cell Therapy • Metastases • Immune cell
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells
    almost2years
    CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (clinicaltrials.gov)
    P1, N=140, Recruiting, National Cancer Institute (NCI) | N=87 --> 140
    Enrollment change
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells
    over2years
    Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Aug 2022 --> Aug 2023
    Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells
    almost3years
    CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (clinicaltrials.gov)
    P1, N=87, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2032 --> Dec 2040 | Trial primary completion date: Dec 2022 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells
    almost3years
    CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (clinicaltrials.gov)
    P1, N=87, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Dec 2021 --> Dec 2022
    Trial primary completion date
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells